StreetInsider.com News Articles

Annovis to Attend the CTAD 2026 with Three Presentations

Thu, 22 Oct 2026 08:00:00 -0400

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, happening November 16-19 in Boston, MA.

Presentation details:

Title: “Restoring proteostasis in Alzheimer's disease with buntanetap, a small-molecule translational inhibitor of neurotoxic proteins”
- Presenter: Alexander Morin, PhD, Director, Strategic Communications
- Type: Oral communications
- Section:

Annovis to Attend the CTAD 2026 with Three Presentations

Thu, 22 Oct 2026 08:00:00 -0400

Presentation details:

Title: “Restoring proteostasis in Alzheimer's disease with buntanetap, a small-molecule translational inhibitor of neurotoxic proteins”
- Presenter: Alexander Morin, PhD, Director, Strategic Communications
- Type: Oral communications
- Section:

Form 8-K Annovis Bio, Inc. For: Oct 19

Tue, 20 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261020/27205906.html

Form SCHEDULE 13G/A Annovis Bio, Inc. Filed by: Empery Asset Management, LP

Thu, 15 Oct 2026 12:34:00 -0400

si-local-file:///var/storage/secattach/20261015/27192353.html

Form DEFA14A Annovis Bio, Inc.

Wed, 07 Oct 2026 09:38:00 -0400

si-local-file:///var/storage/secattach/20261007/27159163.html

Annovis Bio partners with Weave Bio on AI platform for NDA filing

Wed, 23 Sep 2026 08:04:08 -0400

Annovis Bio, Inc. (NYSE: ANVS) announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, to support the planned New Drug Application (NDA) for its investigational drug buntanetap for Alzheimer's disease (AD).

Under the arrangement, Annovis will use Weave Bio's platform for drafting, reviewing, and managing NDA documents. The company's regulatory and clinical teams will retain full responsibility for content, verification, and final approval of all documents submitted to the U.S. Food and Drug Administration (FDA).

"Our goal is to have most of the NDA ready before the data readout, so the path from the top-line results

Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease

Wed, 23 Sep 2026 08:00:00 -0400

MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the planned New Drug Application (NDA) for buntanetap.

Under the collaboration, Annovis will use Weave for drafting, reviewing and managing the NDA documents as the Company heads toward a 6-month top-line data readout from the pivotal Phase

Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease

Wed, 23 Sep 2026 08:00:00 -0400

Under the collaboration, Annovis will use Weave for drafting, reviewing and managing the NDA documents as the Company heads toward a 6-month top-line data readout from the pivotal Phase

Form DEF 14A Annovis Bio, Inc. For: Oct 14

Fri, 11 Sep 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260911/27053491.html

Annovis Bio Inc. (ANVS) PT Lowered to $10 at ThinkEquity

Tue, 08 Sep 2026 06:06:49 -0400

ThinkEquity analyst Ashok Kumar lowered the price target on Annovis Bio Inc. (NYSE: ANVS) to $10.00 (from $20.00) while maintaining a Buy rating.

Annovis to Host Corporate Update Webinar on September 2, 2026

Tue, 25 Aug 2026 08:00:00 -0400

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.

The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upcoming milestones.

Webinar details

Date: Wednesday, September 2, 2026
Time: 4:00 p.m. EDT
Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO
Registration link

Annovis to Host Corporate Update Webinar on September 2, 2026

Tue, 25 Aug 2026 08:00:00 -0400

The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upcoming milestones.

Webinar details

Date: Wednesday, September 2, 2026
Time: 4:00 p.m. EDT
Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO
Registration link

Annovis to Host Corporate Update Webinar on September 2, 2026

Tue, 25 Aug 2026 08:00:00 -0400

The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upcoming milestones.

Webinar details

Date: Wednesday, September 2, 2026
Time: 4:00 p.m. EDT
Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO
Registration link

Annovis to Host Corporate Update Webinar on September 2, 2026

Tue, 25 Aug 2026 08:00:00 -0400

The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upcoming milestones.

Webinar details

Date: Wednesday, September 2, 2026
Time: 4:00 p.m. EDT
Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO
Registration link

Form PRE 14A Annovis Bio, Inc. For: Aug 24

Tue, 25 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260825/26970315.html

Form PRE 14A Annovis Bio, Inc. For: Aug 24

Tue, 25 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260825/26970315.html

Canaccord Reiterates Buy Rating on Annovis Bio Inc. (ANVS)

Tue, 18 Aug 2026 07:00:03 -0400

Canaccord analyst Sumant Kulkami reiterated a Buy rating and $17.00 price target on Annovis Bio Inc. (NYSE: ANVS).

The analyst commented: "ANVS reported its 2Q26 results on 8/17. Operating expenses came in lower at $14.4mn vs. our $18.3mn. Lower R&D, potentially due to timing, which remains difficult to predict, drove the delta vs. our model. Recall, ANVS is developing buntanetap, which is in a Phase 3 trial for early Alzheimer's disease (AD) with 6-month (symptomatic) and 18-month (disease-progression) components. As the company also stated at our recent 46th Annual Growth Conference in Boston, MA (see here ), ANVS reiterated that it

Form 10-Q Annovis Bio, Inc. For: Jun 30

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931632.html

Form 10-Q Annovis Bio, Inc. For: Jun 30

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931632.html

Form 8-K Annovis Bio, Inc. For: Aug 14

Fri, 14 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26930316.html

Form 8-K Annovis Bio, Inc. For: Aug 14

Fri, 14 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26930316.html

Form SCHEDULE 13G Annovis Bio, Inc. Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC

Fri, 14 Aug 2026 12:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26927966.html

Form SCHEDULE 13G Annovis Bio, Inc. Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC

Fri, 14 Aug 2026 12:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26927966.html

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.
Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients with full enrollment projected in Q4 2026.
Annovis will host a corporate update webinar on Wednesday, September 2, 2026, at 4:00 pm EDT.

MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.
Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients with full enrollment projected in Q4 2026.
Annovis will host a corporate update webinar on Wednesday, September 2, 2026, at 4:00 pm EDT.